

1   **ABSTRACT OF THE DISCLOSURE**

2                 The present invention relates to a method for treating immune  
3   disorders and a method for lowering the levels of T-cell activation and  
4   proliferation in a human comprising administering CD30 or a biologically  
5   functional equivalent thereof to a human afflicted with immune disorders. The  
6   present invention also relates to a pharmaceutical composition for treating  
7   immune disorders in a human comprising a therapeutically effective amount of  
8   CD30 or a biologically functional equivalent thereof, and a pharmaceutically  
9   acceptable carrier, excipient or diluent.